Eli Lilly and Co. received approval from the U.S. FDA for CYRAMZA (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. With this approval, CYRAMZA has now received six FDA approvals to treat certain types of lung, liver, stomach and colorectal cancers. CYRAMZA plus erlotinib is the first and only FDA-ap...